Stabilizing RNA Lipid Nanoparticles for Nebulized Pulmonary Delivery

Study Background and Research Question

RNA therapeutics, including mRNA and siRNA, have emerged as promising tools for treating a broad spectrum of pulmonary disorders, such as genetic diseases and viral infections. While lipid nanoparticles (LNPs) are the gold standard for RNA encapsulation and delivery, most clinically used LNPs accumulate in the liver when administered intravenously, limiting their efficacy for lung-targeted therapies. Direct pulmonary delivery via nebulization—a process that creates inhalable aerosols—has the potential to overcome this limitation by targeting the respiratory tract non-invasively. However, the high shear forces during nebulization can destabilize LNPs, leading to cargo loss and diminished delivery efficiency. The primary research question addressed by the reference study (Slaughter et al., 2025) is: How can we stabilize RNA-loaded LNPs during nebulization without compromising their bioactivity or delivery efficiency?

Key Innovation from the Reference Study

The study introduces a generalizable, composition-agnostic strategy to protect RNA LNPs during nebulization by optimizing the buffer environment. Instead of modifying the LNP lipid composition—which can inadvertently affect potency or cellular uptake—the authors systematically tested different buffer constituents to identify conditions that preserve nanoparticle properties and encapsulated RNA under the mechanical stresses of nebulization. This innovation decouples the challenges of formulation design from those of delivery, expanding the toolkit for developing inhaled RNA therapeutics.

Methods and Experimental Design Insights

LNPs were formulated with a clinically validated lipid composition (Onpattro®-like formulation) and loaded with RNA cargo. The team evaluated multiple buffer systems, focusing on parameters such as pH, osmolarity, and the inclusion of stabilizing excipients. Key variables included:

• Buffer pH (notably pH 5.0 citrate buffer)
• Presence of poloxamer 188 (a nonionic surfactant)
• Glucose for isoosmotic conditions

The particles were subjected to nebulization, and subsequent analyses included hydrodynamic diameter (via dynamic light scattering), RNA encapsulation efficiency, nanoparticle recovery, and functional bioactivity (using cellular uptake and siRNA-mediated gene silencing in Vero cells expressing nano luciferase). The design allowed for direct assessment of how each buffer component influenced LNP stability and therapeutic potential post-nebulization.

Protocol Parameters

• Nebulization buffer: pH 5.0 sodium citrate buffer is recommended to preserve LNP electrostatic interactions and reduce RNA leakage during aerosolization.
• Excipient choice: Addition of 0.01–0.1% poloxamer 188 helps maintain nanoparticle size and improves recovery rates post-nebulization.
• Osmolarity control: 5% (w/v) glucose is used to achieve isoosmotic conditions, minimizing aggregation and maintaining LNP integrity.
• RNA cargo: Both mRNA and siRNA can be encapsulated; functional assays used nano luciferase reporter systems to validate bioactivity in vitro.
• Particle analysis: Post-nebulization, assess hydrodynamic diameter and encapsulation efficiency to confirm stability before proceeding to cellular bioactivity assays.

Core Findings and Why They Matter

The authors found that LNPs nebulized in pH 5.0 citrate buffer exhibited significantly reduced RNA leakage compared to neutral pH buffers. Poloxamer 188 further stabilized particle size and improved recovery after nebulization, while glucose ensured isoosmotic conditions, reducing aggregation. Importantly, RNA delivered in LNPs after nebulization retained functional activity, as shown by effective cellular uptake and siRNA-induced knockdown of a luciferase reporter gene. These results confirm that buffer optimization can robustly preserve both the structural and functional integrity of RNA-loaded LNPs during the physical stresses of aerosolization (Slaughter et al., 2025).

This approach enables broader applicability across different RNA cargos and LNP formulations, addressing a major bottleneck in the translation of inhaled nucleic acid therapeutics. Efficient bioluminescent reporter gene systems—such as those leveraging Firefly Luciferase mRNA—benefit from these improvements by providing more reliable and reproducible functional readouts in pulmonary delivery models.

Comparison with Existing Internal Articles

The reference study’s buffer-centric stabilization strategy complements and extends insights from recent advances in mRNA chemistry and delivery. For instance, internal reviews highlight how 5-moUTP-modified, Cap 1–capped Firefly Luciferase mRNA offers enhanced translation efficiency, reduced innate immune activation, and improved mRNA stability. While those articles primarily focus on the molecular engineering of the mRNA (e.g., through 5-methoxyuridine modifications and optimized poly(A) tails), the present paper addresses the physical delivery bottleneck—specifically, how to maintain integrity during nebulization regardless of mRNA sequence or modifications.

Moreover, workflow guides such as "Applied Firefly Luciferase mRNA: Protocols, Performance, and Pitfalls" provide practical guidance for handling and transfection of advanced reporter mRNAs in cellular and preclinical models. The current study bridges the gap by ensuring that the delivery vehicle and mRNA cargo maintain their properties during the critical step of aerosol-based administration—a challenge not directly addressed in prior mRNA optimization literature.

Limitations and Transferability

While the buffer-based stabilization approach is generalizable across LNP formulations and RNA types, several limitations exist. The study was conducted primarily in vitro and with cell-based functional assays; in vivo validation in animal models or clinical settings remains a necessary next step to confirm translatability and safety. Additionally, while the method is designed to be lipid composition-agnostic, interactions with specific therapeutic cargos or patient-derived materials could yield different outcomes. The choice of buffer and excipient concentrations may require empirical optimization for distinct applications, especially when moving from small-scale lab experiments to clinical-grade aerosol delivery.

Research Support Resources

For researchers aiming to model or quantify mRNA delivery and translation efficiency in pulmonary or other biological systems, utilizing standardized bioluminescent reporter mRNAs is essential. Products like EZ Cap™ Firefly Luciferase mRNA (5-moUTP) (SKU R1013) offer a robust, 5-moUTP-modified, Cap 1–capped reporter with enhanced stability and reduced immunogenicity for such workflows. These reagents are well-suited for translation efficiency assays, cell viability studies, and bioluminescent imaging, and can be directly integrated into LNPs for delivery studies as described in the reference work. As always, proper handling and buffer compatibility should be validated for optimal experimental outcomes.